Core Insights - Shattuck Labs, Inc. is developing SL-325, a high-affinity DR3 blocking antibody for the treatment of inflammatory bowel disease (IBD), with positive preclinical data indicating no toxicity or residual agonism in non-human primates [1][4][5] - The company plans to file an Investigational New Drug (IND) application in the third quarter of 2025, with Phase 1 clinical trials expected to commence later this year [1][4][5] Preclinical Data - SL-325 demonstrated complete and durable DR3 receptor occupancy at low doses in non-human primates, with no observed adverse effects or organ dysfunction [5][6] - The pharmacokinetic profile suggests extended dosing intervals in humans, with projected dosing of 1 mg/kg every two weeks for induction and 3 mg/kg every two weeks for maintenance [5][6] Mechanism of Action - Inhibition of the TL1A/DR3 signaling axis by SL-325 shows complete remission rates that match or exceed those of existing therapies, indicating a potentially more effective treatment option for IBD [2][4] - The antibody's design aims for a more complete blockade of the DR3/TL1A pathway compared to TL1A blocking antibodies, leveraging the higher expression of DR3 in IBD patients [2][4] Company Overview - Shattuck Labs specializes in developing treatments for autoimmune and inflammatory diseases, with a focus on novel therapeutics targeting TNF superfamily receptors [5][6] - The company operates from Austin, Texas, and Durham, North Carolina, and emphasizes its expertise in protein engineering [6]

AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming oral presentation at the 20th Congress of ECCO in Inflammatory Bowel Diseases 2025 being held in Berlin, Germany from February 19–22, 2025. This presentation will featu ...

AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming oral presentation at the 20th Congress of ECCO in Inflammatory Bowel Diseases 2025 being held in Berlin, Germany from February 19–22, 2025. This presentation will featur ...

AUSTIN, TX and DURHAM, NC, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming poster presentation at the 2025 Crohn’s and Colitis Congress being held in San Francisco, California from February 6–8, 2025. Presentation DetailsFormat: Poster prese ...

AUSTIN, TX and DURHAM, NC, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming poster presentation at the 2025 Crohn's and Colitis Congress being held in San Francisco, California from February 6–8, 2025. Presentation DetailsFormat: Poster presen ...

AUSTIN, TX and DURHAM, NC, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present a corporate update and participate in one-on-one meetings at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, C ...

Financial Performance - Cash and cash equivalents and investments as of September 30, 2024, were approximately $90.1 million, down from $101.1 million as of September 30, 2023, representing a decrease of about 10.0%[2] - The net loss for Q3 2024 was $16.7 million, or $0.33 per share, compared to a net loss of $27.5 million, or $0.65 per share, in Q3 2023, indicating an improvement of 39.5%[2] - Total assets as of September 30, 2024, were approximately $111.7 million, down from $159.6 million as of December 31, 2023, a decrease of about 30.0%[8] - Total liabilities as of September 30, 2024, were $15.1 million, slightly up from $14.9 million as of December 31, 2023[8] Expenses - Research and Development (R&D) expenses for Q3 2024 were $16.3 million, a decrease of 32.0% compared to $24.2 million in Q3 2023[2] - General and Administrative (G&A) expenses for Q3 2024 were $4.6 million, down from $5.1 million in Q3 2023, reflecting a reduction of approximately 9.8%[2] Strategic Initiatives - The company announced the development of SL-325, a first-in-class DR3 antagonist antibody, with an IND filing expected in Q3 2025[1] - The company has completed its restructuring plans to focus on SL-325 and has substantially reduced its workforce associated with the discontinuation of SL-172154[3] Future Outlook - Shattuck Labs expects its cash and cash equivalents to fund operations into 2027, based on current operational plans[3] - The company plans to participate in investor conferences, including the Piper Sandler & Co. 36th Annual Healthcare Conference from December 3-5, 2024[2]

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (NASDAQ: STTK). Investors who purchased Shattuck securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/STTK. Investigation Details On October 1, 2024, Shattuck issued a press release announcing the discontinuation of its lea ...

Shattuck Labs, Inc. (STTK) has been on a downward spiral lately with significant selling pressure. After declining 69% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether ...

Core Viewpoint - Shattuck Labs has decided to discontinue the development of its pipeline candidate SL172154 for acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) due to limited efficacy and strategic prioritization efforts, leading to a significant drop in stock price [1][4]. Pipeline and Clinical Development - SL172154 was the only clinical-stage candidate in Shattuck's pipeline, and its discontinuation disappointed investors [1]. - The Phase IB study of SL172154 combined with Bristol Myers' Vidaza/Onureg showed a median overall survival (OS) of 10.6 months for HR-MDS patients, which is not expected to improve significantly [2]. - In the AML arm, the combination treatment resulted in a median OS of 10.5 months, also not expected to improve significantly [3]. - The benchmark median OS for TP53 mutant HR-MDS patients treated with Vidaza/Onureg monotherapy is approximately 9-12 months, while for TP53 mutant AML patients, it is about five to eight months [2][3]. Financial and Strategic Implications - Shattuck's stock has plummeted 73.1% year-to-date, compared to a 1.2% decline in the industry [6]. - The company has terminated its collaboration deal with Ono Pharmaceutical, which may further limit its income potential [8][9]. - Following the discontinuation of SL172154, Shattuck has identified its preclinical candidate SL-325 as the lead for initial clinical development in inflammatory bowel disease, with plans to file an investigational new drug application by Q3 2025 [10][11]. - The company plans to reduce its workforce by about 40% to focus resources on SL-325 development [12]. - As of June 30, 2024, Shattuck had cash and cash equivalents of $105.3 million, which is expected to fund operations through 2027 [13].